T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy with the ability to target cancer cells through inherent mechanisms of the immune system. The method works by infusing tumor-specific cytotoxic T cells into patients which will recognize, target and attack tumor cells.

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Researchers identify key protein required for optimal immune responses to cancer

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.

2 Jun 2020

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a “tumor-tropic liposome technology” for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

30 May 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

CanSino's potential coronavirus vaccine triggers immune response in clinical trial

Scientists across the globe are racing to develop a vaccine that can provide protection against coronavirus disease (COVID-19). An effective and safe vaccine would curb not only the current coronavirus pandemic but also prevent future outbreaks

27 May 2020

Many different T cell receptors recognize SARS-CoV-2 antigenic sites

The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading over the world. However, not much is known about how the adaptive immune response kicks in following the viral challenge. This knowledge is crucial to predicting the efficacy of a vaccine and estimating the chances of reinfection.

26 May 2020

First COVID-19 vaccine found to be safe, able to generate rapid immune response in phase 1 clinical trial

The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet.

22 May 2020

Different immune responses can occur in Covid-19, shows study

The human immune system is reactive to more than just the viral protein on which researchers have focused to date. This is relevant for tests and potential vaccines.

22 May 2020

IL-6 blocker use in severe COVID-19 increases risk of secondary infections

With many hundreds of thousands of deaths due to the current COVID-19 pandemic, there is a rush to find an effective vaccine or drug against the virus. A new study on the preprint server medRxiv* in May 2020 shows that the use of some biologically plausible drugs may be counterproductive, and care should be taken when trying out unproven therapies.

22 May 2020

Computational immunology paves the way for SARS-CoV-2 peptide cocktail vaccine candidate

By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.

21 May 2020

Lattice light-sheet microscopy could help in drug and vaccine development

From testing drugs to developing vaccines, the close study of the immune system is key to improving real-world health outcomes. T-cells are integral to this research, as these white blood cells help tailor the body's immune response to specific pathogens.

21 May 2020

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two study PrE0505 for the initial treatment of patients with malignant pleural mesothelioma.

20 May 2020

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit

Oxford Immunotec Global PLC, a global, high-growth diagnostics company, today announces the release of the T-SPOT Discovery SARS-CoV-2 test kit.

19 May 2020

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable parts of the body. Now, a City of Hope molecular scientist thinks he may have found a way to prevent ineffective surgeries and prolong the lives of these patients.

18 May 2020

Boehringer Ingelheim acquires Northern Biologics to expand cancer immunology portfolio

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging area in cancer immunology.

From Boehringer Ingelheim International GmbH 18 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Chasing the elusive dream of a COVID cure

Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.

15 May 2020

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments.

14 May 2020

A 'window of vulnerability' for re-infection with HIV after stem cell transplantation

Some people with HIV need to undergo an allogeneic stem cell transplantation in order to treat different types of blood cancer. Most of the patient's immune cells are eliminated during these transplantations.

14 May 2020

Does HIV infection increase the severity of COVID-19?

A new study by researchers at the New York University Grossman School of Medicine and published on the preprint server medRxiv* in May 2020 reports that being infected with HIV at the time of acquiring COVID-19 does not significantly increase the severity of illness or the risk of complications.

13 May 2020

Finding new therapeutic strategies for aggressive T-cell acute lymphoblastic leukemia

Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.

12 May 2020

1
2
3
4
...
2050
Next

T Cell

Overview

Adoptive T Cell Therapy Applications

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Latest T Cell News and Research

Researchers identify key protein required for optimal immune responses to cancer

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

CanSino's potential coronavirus vaccine triggers immune response in clinical trial

Many different T cell receptors recognize SARS-CoV-2 antigenic sites

First COVID-19 vaccine found to be safe, able to generate rapid immune response in phase 1 clinical trial

Different immune responses can occur in Covid-19, shows study

IL-6 blocker use in severe COVID-19 increases risk of secondary infections

Computational immunology paves the way for SARS-CoV-2 peptide cocktail vaccine candidate

Lattice light-sheet microscopy could help in drug and vaccine development

Durvalumab plus chemotherapy improved overall survival rate for mesothelioma patients

Oxford Immunotec releases the T-SPOT® Discovery™ SARS-CoV-2 kit

Novel microRNA biomarker could help detect lymph node metastases in pancreatic cancer patients

Boehringer Ingelheim acquires Northern Biologics to expand cancer immunology portfolio

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Chasing the elusive dream of a COVID cure

More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggests

A 'window of vulnerability' for re-infection with HIV after stem cell transplantation

Does HIV infection increase the severity of COVID-19?

Finding new therapeutic strategies for aggressive T-cell acute lymphoblastic leukemia

Silent hypoxia and its role in COVID-19 detection

Using Lung Simulators to Help Tackle COVID-19

Predicting How Contact Tracing Can Control the Spread of COVID-19

T Cell

Overview

Latest T Cell News and Research

Newsletters you may be interested in